Merit Medical Systems (NASDAQ:MMSI) Given New $95.00 Price Target at JPMorgan Chase & Co.

Merit Medical Systems (NASDAQ:MMSI) had its target price boosted by equities researchers at JPMorgan Chase & Co. from $77.00 to $95.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 11.23% from the stock’s previous close.

A number of other analysts also recently commented on the company. Piper Sandler increased their price target on Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research report on Friday. Raymond James Financial restated an “outperform” rating and issued a $100.00 price objective on shares of Merit Medical Systems in a research note on Friday. Robert W. Baird set a $98.00 target price on Merit Medical Systems in a research report on Friday. Wall Street Zen cut Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 5th. Finally, Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $100.30.

Merit Medical Systems Stock Up 2.5%

Shares of NASDAQ:MMSI traded up $2.06 during midday trading on Friday, hitting $85.41. 1,089,149 shares of the company’s stock were exchanged, compared to its average volume of 802,092. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. Merit Medical Systems has a 12 month low of $59.74 and a 12 month high of $94.75. The company has a market cap of $5.09 billion, a PE ratio of 37.08, a price-to-earnings-growth ratio of 2.51 and a beta of 0.52. The stock has a 50 day moving average price of $69.45 and a 200-day moving average price of $71.69.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The company had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same period last year, the firm earned $1.01 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, sell-side analysts anticipate that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

Insider Buying and Selling at Merit Medical Systems

In other news, insider Brian G. Lloyd bought 2,000 shares of the stock in a transaction on Thursday, May 7th. The shares were purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the purchase, the insider directly owned 2,000 shares in the company, valued at $125,240. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its position in shares of Merit Medical Systems by 1.5% in the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock valued at $196,645,000 after purchasing an additional 32,459 shares during the period. Conestoga Capital Advisors LLC grew its stake in Merit Medical Systems by 3.9% in the 1st quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock valued at $149,407,000 after buying an additional 81,030 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after buying an additional 234,682 shares in the last quarter. Wellington Management Group LLP raised its holdings in Merit Medical Systems by 7.0% during the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after acquiring an additional 86,504 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Merit Medical Systems by 1.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock valued at $85,287,000 after acquiring an additional 12,285 shares during the period. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems News Roundup

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong Q2 earnings beat: Second-quarter adjusted EPS was $1.19, up 18% year over year and well above the $0.96 consensus estimate. Revenue increased 9.5% to $418.8 million, exceeding expectations of $405.3 million. MMSI Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Margin expansion and broad growth: GAAP operating margin improved to 14.4% from 12.3%, while non-GAAP operating margin reached 22.6% versus 21.2% a year earlier. Management cited growth across product categories, with organic constant-currency revenue also rising 9%. Merit Medical Reports Second Quarter Results
• Positive Sentiment: 2026 guidance raised: The company now expects full-year adjusted EPS of $4.25 to $4.35, above the approximately $3.98 analyst consensus, signaling stronger anticipated profitability. Merit Medical Raises 2026 Outlook
• Positive Sentiment: Analyst targets increased: Needham raised its target to $101 and BTIG lifted its target to $105; both maintained Buy ratings. Needham Price Target Increase
• Neutral Sentiment: Wells Fargo raised its target to $83 but retained an Equal Weight rating, implying the stock may already reflect much of the recent improvement. Wells Fargo Analyst Update
• Negative Sentiment: Year-to-date operating cash flow fell 11% and free cash flow declined 14%, a potential concern despite the stronger earnings performance. The shares also trade at a relatively elevated forward valuation following the rally.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.